Alzheimer's Has a Seeing Problem. This Brain Scan Could Fix It.

Head-to-head lab studies have also found that MK-6240 has higher in vitro affinity for Alzheimer's brain tissue than flortaucipir, though postmortem autoradiography studies found nearly identical binding profiles and broadly similar tissue selectivity for AD-type tau.

The Bigger Picture: Better Diagnosis Unlocks Better Treatment

This isn't just about a prettier brain scan. The Alzheimer's treatment landscape is transforming, and the diagnostics need to keep pace.

Lecanemab and donanemab (both amyloid-targeting antibodies) require patients to prove they have amyloid buildup before starting treatment. That's currently the gatekeeper. But tau PET plays a different, increasingly important role: risk stratification. In plain English, it helps doctors figure out which patients are most likely to actually benefit from these expensive, sometimes risky therapies.

Patients with lower tau burden may see more meaningful slowing of their decline, while those with extensive tau spread may be too far along. Without a good tau scan, doctors are essentially guessing at that part of the equation.

And the safety stakes are real. Both lecanemab and donanemab carry the risk of ARIA (amyloid-related imaging abnormalities), which can cause brain swelling or microbleeds. In Europe, regulators have already restricted use of lecanemab to lower-risk patients due to ARIA concerns. Every tool that helps doctors pick the right patient for the right drug at the right time becomes more valuable as these therapies roll out globally.

Already a Research Workhorse

Even before any FDA decision, MK-6240 has been quietly building its résumé. Lantheus says the tracer is already being used in nearly 100 ongoing clinical trials and by more than 16 pharmaceutical companies. That's not a coincidence; researchers have been choosing it because of its performance characteristics.

That research footprint matters commercially, too. If MK-6240 gets approved, it won't be starting from zero. Neurologists and researchers already know how to read its scans and trust its data. That kind of familiarity can accelerate adoption in ways that marketing dollars alone can't buy.

Lantheus' Bigger Bet on PET

Lantheus isn't a one-trick pony here. The company has been deliberately reshaping itself around PET radiodiagnostics, selling off its legacy SPECT imaging business and doubling down on next-generation tracers. MK-6240 sits alongside the company's PSMA imaging program (used in prostate cancer) as a cornerstone of that strategy.

The company acquired MK-6240 in February 2023 by purchasing Cerveau Technologies, which held the development and commercialization rights. Lantheus guided full-year 2025 revenue in the $1.49 to $1.51 billion range, with MK-6240 still in pre-launch mode. Analysts seem to view the tau tracer as more of a 2027 growth driver than an immediate 2026 revenue contributor, with the real commercial ramp coming after launch, coding, and reimbursement infrastructure are in place.

Another next-gen tracer called PI-2620 is also in development elsewhere, so Lantheus won't have the upgraded-tau-imaging market to itself forever. But being first (or second, after Tauvid) with a potentially better mousetrap is a strong position.

What Comes Next

The FDA's decision on MK-6240 could reshape how Alzheimer's patients are diagnosed and sorted into treatment pathways. It's not a cure. It's not even a treatment. It's a diagnostic tool. But in a disease where picking the right patient for the right drug is becoming the central challenge, seeing the problem clearly is half the battle.

We're waiting on confirmation of the FDA's final call. Stay tuned.